Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals

Diagnostic Microbiology and Infectious Disease

Volumn 35, Issue 1, 1999, Pages 1-7

  Karlowsky, James A ^a   Zhanel, George G ^a   Hoban, Daryl J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINAFLOXACIN; GENTAMICIN; NALIDIXIC ACID; OFLOXACIN; SPARFLOXACIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CONTROLLED STUDY; ENTEROCOCCUS; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

CANADA; CROSS INFECTION; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 0033200235     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00045-0     Document Type: Article

References (21)

1. Bacquero F. Gram-positive resistance Challenge for the development of new antibiotics . J Antimicrob Chemother. 39:(suppl A):1997;1-6.
2. Barry A.L., Fuchs P.C., Brown S.D. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother. 39:(suppl A):1997;87-92.
3. Bouanchaud D.H. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother. 39:(suppl A):1997;15-21.
4. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 42:1993;597-599.
5. Recommendations for preventing the spread of vancomycin resistance. MMWR Morb Mortal Wkly Rep. 42:(RR-12):1997;1-19.
6. Clark N.C., Cooksey R.C., Hill B.C., Swenson J.M., Tenover F.C. Characterization of glycopeptide resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother. 37:1993;2311-2317.
7. Currie B.P., Gnass S., Levi M.H. A hospital based stool culture survey to detect vancomycin resistant enterococcus (VRE) - Utility and application. Infect Control Hosp Epidemiol. 16:(part 2 suppl):1995;P18. (Abstr 15).
8. Dutka-Malen S., Evers S., Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol. 33:1995;24-27.
9. Emerging epidemiology of vancomycin-resistant enterococci in Canada (1997) Can J Infect Dis 8:182-185.
10. French G.L. Enterococci and vancomycin resistance. Clin Infect Dis. 27:(suppl 1):1998;S75-S83.
11. Harwick H.J., Kalmanson G.M., Guze L.B. In vitro activity of ampicillin or vancomycin combined with gentamicin or streptomycin against enterococci. Antimicrob Agents Chemother. 4:1973;383-387.
12. Jones R.N., Ballow C.H., Biedenbach D.J., Deinhart J.A., Schentag J.J. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 30:1998;437-451.
13. Kirst H.A., Thompson D.G., Nicas T.I. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 42:1998;1303-1304.
14. Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria that Grow Aerobically Approved Standard M7-A4 . 1997;NCCLS, Wayne, PA.
15. Performance Standards for Antimicrobial Susceptibility Testing Ninth Informational Supplement. M100-S9 . 1999;NCCLS, Wayne, PA.
16. Ofner-Agostini M.E., Conly J., Paton S., Kureishi A., Nicolle L., Mulvey M., Johnson W., Johnston L. Vancomycin-resistant enterococci (VRE) in Canada - results of the Canadian nosocomial infection surveillance program 1996 VRE point prevalence surveillance project. Can J Infect Dis. 8:1997;73-78.
17. Segal-Maurer S., Urban C., Rahal J.J. Current perspectives on multidrug-resistant bacteria. Infect Dis Clin N Amer. 10:1996;939-956.
18. Toala P., McDonald A., Wilcox C., Finland M. Susceptibility of group D Streptococcus (Enterococcus) to 21 antibiotics in vitro with special reference to species differences. Am J Med Sci. 258:1969;416-430.
19. Turenne C.Y., Hoban D.J., Karlowsky J.A., Zhanel G.G., Kabani A.M. The addition of the methyl-α-D-glucopyranoside test is necessary for differentiation of clinically relevant Enterococcus species. J Clin Microbiol. 36:1998;2333-2335.
20. Uttley A.H.C., Collins C.H., Naidoo J., George R.C. Vancomycin-resistant enterococci. Lancet. 1:1988;57-58.
21. Williams J.D., Maskell J.P., Whiley A.C., Sefton A.M. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. J Antimicrob Chemother. 39:(suppl A):1997;41-46.